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Both iron deﬁciency (ID) and malaria are common among African children. Studies show that the iron-regulatory
hormonehepcidin is induced bymalaria, but few studies have investigated this relationship longitudinally.Wemea-
sured hepcidin concentrations,markers of iron status, and antibodies tomalaria antigens during two cross-sectional
surveys within a cohort of 324 Kenyan children ≤8 years oldwhowere under intensive surveillance formalaria and
other febrile illnesses. Hepcidin concentrations were the highest in the youngest, and female infants, declined rap-
idly in infancy andmore gradually thereafter. Asymptomaticmalaria andmalaria antibody titres were positively as-
sociated with hepcidin concentrations. Recent episodes of febrile malaria were associated with high hepcidin
concentrations that fell over time. Hepcidin concentrations were not associated with the subsequent risk of either
malaria or other febrile illnesses. Given that iron absorption is impaired by hepcidin, our data suggest that asymp-
tomatic and febrile malaria contribute to the high burden of ID seen in African children. Further, the effectiveness
of iron supplementation may be sub-optimal in the presence of asymptomatic malaria. Thus, strategies to prevent
and eliminate malaria may have the added beneﬁt of addressing an important cause of ID for African children.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Malaria and iron deﬁciency (ID) are major public health problems
for children living in sub-Saharan Africa. Malaria caused an estimated
437,000 deaths in young African children in 2013 (WHO, 2014) and
N70% of children have asymptomatic malaria in some malaria-
endemic areas (Houngbedji et al., 2015), while ID is thought to impair
cognitive development (Black et al., 2011) and is the leading cause of
years lived with disability in sub-Saharan Africa (Vos et al., 2012).
Hepcidin, the iron-regulatory hormone, may provide a critical link be-
tweenmalaria and ID. Hepcidin controls the absorption and distribution
of iron (Ganz, 2013) and is thought to play a role in the innate immune
response by restricting iron availability for pathogen growth (Ganz,
2009; Drakesmith and Prentice, 2012). The synthesis of hepcidin is reg-
ulated by diverse, often competing, physiological processes, including
iron stores, inﬂammation and erythropoietic drive (Ganz, 2011;
Atkinson et al., 2014). Malaria also alters hepcidin concentrations. Fe-
brile malaria is associated with increased plasma concentrations
(Howard et al., 2007; de Mast et al., 2009; Casals-Pascual et al., 2012;
Ayoya et al., 2009), while severe and complicated malaria is associated
with reduced plasma levels in African children (Casals-Pascual et al.,
2012; Burte et al., 2013). Asymptomatic malaria also increased plasma
levels in Indonesian school-age children (de Mast et al., 2010). In turn,
we hypothesized that hepcidin may mediate the risk of malaria
and other infections by restricting iron availability (Ganz, 2009;
Drakesmith and Prentice, 2012). Intriguing data from mouse models
suggest that hepcidin may play a critical role in host defence against
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malaria (Wang et al., 2011), malaria superinfection (Portugal et al.,
2011), and bacterial infection (Arezes et al., 2015), but how this may
work in children is not known. In the current study, our objectives
were to assess the effect of a range of factors including age, gender
and malaria on hepcidin concentrations and in turn to assess the effect
of hepcidin concentrations on subsequent infectious risk in a longitudi-
nal surveillance study of Kenyan children intensivelymonitored forma-
laria and other febrile illnesses.
2. Materials and Methods
2.1. Ethics Statement
Individual written informed consent was obtained from the parents
of all study participants and ethical permission for the study was
granted by the Kenya Medical Research Institute (KEMRI)/National
Ethical Review Committee.
2.2. Participants and Procedures
The current studywas nestedwithin an ongoing, longitudinal cohort
study evaluating the history and acquisition of natural immunity toma-
laria in children living in Kiliﬁ District on the Kenyan coast (Mwangi
et al., 2005). The current study involving 324 children was conducted
during an 18-month period between November 2001 and May 2003
and included all children b8 years of age within the Ngerenya study
area (Fig. 1). Participantsweremonitored formalaria and other diseases
by weekly active surveillance as previously described (Mwangi et al.,
2005). Two cross-sectional surveys were conducted at 6 and 12months
after the start of the study duringwhich venous blood sampleswere col-
lected. Children exited the study if informed consent was withdrawn or
if they moved out of the study area for a period of N2 months.
2.3. Laboratory Procedures
Plasmodium falciparum parasitaemia was determined as previously
described (Nyakeriga et al., 2004). Haemoglobin typing (HbA and HbS)
was by electrophoresis (Helena Laboratories, Beaumont, TX) while α-
thalassemia genotyping was by PCR (Chong et al., 2000). Plasma concen-
trations of ferritin, soluble transferrin receptor (sTfR) and C-reactive pro-
tein (CRP) were determined as previously described (Atkinson et al.,
2014; Nyakeriga et al., 2004). IgG antibodies against whole P. falciparum
schizont extract and against the 3D7 allele of apical membrane antigen
1 (AMA1) and merozoite surface protein 2 (MSP2) were assayed by en-
zyme linked immunosorbent assay (ELISA) (Mugyenyi et al., 2013).
Plasma hepcidin was quantiﬁed by competitive ELISA (Hepcidin-25
(human) EIA Kit, Bachem) (Atkinson et al., 2014). Standards and samples
were analyzed in duplicate or triplicate. Samples giving readings outside
the standard linear region were repeated at appropriate dilutions. Read-
ings with coefﬁcient of variation N10% were repeated. The lower limit
of detection (LOD) of hepcidin was estimated at 0.08 ng/ml based on
the hepcidin value corresponding to 3 standard deviations below the
mean no hepcidin blank optical density at 450 nm; undiluted samples
giving reading of bLOD were reported as LOD/2 = 0.04 ng/ml.
2.4. Case Deﬁnitions
Clinical malaria was deﬁned as a fever (axillary temperature
≥37.5 °C) in conjunction with a positive blood smear for P. falciparum
parasites at any density for children age b1 year or at a density of
N2500 parasites/μl for children age ≥1 year (Mwangi et al., 2005).
Asymptomatic malaria was deﬁned during cross-sectional surveys as
smear positive P. falciparum malaria in the absence of fever or other
symptoms of clinical illness, while non-malarial fever was deﬁned as a
fever in conjunctionwith a negativemalaria blood smear. Inﬂammation
was deﬁned as plasmaCRP concentration of ≥5mg/l (WHO, CDC, 2007).
ID was deﬁned as a ferritin concentration of b12 μg/l, or b30 μg/l in
the presence of inﬂammation respectively (Atkinson et al., 2014;
WHO/UNICEF/UNU, 2001). The ferritin index, a measure of bone
marrow iron depletion, was deﬁned as soluble transferrin receptor/log
ferritin (Punnonen et al., 1997).
2.5. Statistical Analyses
All analyses were conducted using STATA v.12.0 (StataCorp. College
Station, TX). Associations between hepcidin concentration (or other
variables such as iron status) and independent parameters were evalu-
ated using generalized estimating equation (GEE)-based linear regres-
sion models that included an exchangeable correlation structure and a
robust variance estimator to account for correlation between measure-
ments at two time points from the same child. Analyses were age-
adjusted as appropriate. We did not restrict ﬁtting independent param-
eters, such as age, to linear effects. We allowed for nonlinear effects by
ﬁtting and signiﬁcance testing multivariable fractional polynomials
with use of the Royston and Altman algorithm entering hepcidin con-
centration and other variables simultaneously in the model. This
allowed the model to optimize the model ﬁt using power and log func-
tions to approximate the shape of the relationship of the parameter
with hepcidin (Royston and Altman, 1994). The association between
hepcidin concentration and the subsequent risk of clinical malaria or
non-malarial fever was evaluated using Cox proportional hazards anal-
ysis during the 6-month period of monitoring after each cross-sectional
survey. Therefore, each of the 324 children could contribute up to 2
periods of observation and the sandwich estimator was used to cluster
analysis by individual (Armitage et al., 2001).
Multivariable models included covariates with a signiﬁcance of
p ≤ 0·1 in univariablemodels.We used p b 0·05 to interpret theﬁndings
in the ﬁnal multivariablemodel. For clinical malaria hazards ratios were
adjusted for age, ethnicity, sickle cell trait and period of monitoring and
Fig. 1. Study construction. A total of 324 childrenwere recruited to the study; 245 contributed data to both theMay and October surveys, 48 to theMay survey only and 31 to the October
survey only.
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for non-malarial fever hazards ratios were adjusted for age in years and
period of monitoring.
2.6. Role of the Funding Source
This work was funded by the Oxford University Clinical Academic
Graduate School; The Academy of Medical Sciences with TheWellcome
Trust, The British Heart Foundation, Arthritis Research UK (to SHA); a
Beit Memorial Fellowship forMedical Research; anMRCNew Investiga-
tor award; the National Institute for Health Research Oxford Biomedical
Research Centre (to HD); a Senior Wellcome Trust Fellowship (grant
number 091758 to TNW); a Senior Research Fellowship to JGB; and
the EuropeanUnion Framework Programme Seven EuropeanVirtual In-
stitute ofMalaria Research Consortium (grant number 242095 to TNW).
The sponsors had no role in study design, data collection, data analyses,
data interpretation, or writing of the report. The corresponding author
had full access to all data in the study and the ﬁnal responsibility for
the decision to submit for publication.
3. Results
A total of 324 children were included in the study with an average
followup time of 7·4 months. Table 1 describes the characteristics of
the study population. Median age was 47·0 months at the mid-point
of longitudinal follow-up (range; 4·9 to 97·1 months) and 54·6%
were male. The overall geometric mean plasma hepcidin concentration
was 2·45 ng/ml (95% CI; 2·08, 2·90; range; 0·04 to 176·56 ng/ml). ID
and inﬂammation were common at 46% (262/572) and 18% (102/572)
respectively. Asymptomatic malaria parasitaemia was also common:
12% (70/582) of routine blood smears were positive for P. falciparum
with a mean parasite density of 909 parasites/μl (range; 40 to 380,000
parasites/μl). We found no signiﬁcant association between geometric
mean hepcidin concentrations and either sickle cell trait (for HbAA
2·48 ng/ml; 95% CI 2·08, 2·97; and for HbAS 2·15 ng/ml; 1·32, 3·50;
p = 0·63) or α-thalassaemia (for αα/αα 2·64 ng/ml; 95% CI 1·96,
3·56; for−α/αα 2·31 ng/ml; 1·82, 2·93; p = 0·56 and for−α/−α
2·27 ng/ml; 1·48, 3·50; p = 0·61).
3.1. Hepcidin Concentration Varies by Age and in Infancy by Sex
Plasma hepcidin concentration varied markedly by age (ß=−0·1;
−0·06,−0·13; p b 0·0005 in a GEE-based model), while the best-ﬁt
fractional polynomial for the age proﬁle of hepcidin suggested that
levels were the highest in the youngest children, decreased very rapidly
in infancy and then declined slowly in childhood (Fig. 2A). These ﬁnd-
ingsmay be explained by age-related differences in the strengthof stim-
uli determining hepcidin expression. The best-ﬁt for the age proﬁle of
ferritin suggested that levels fell very rapidly in infancy reaching a
nadir between 1 and 2 years of age and then gradually increased. Solu-
ble TfR levels and the ferritin index increased sharply in infancy, while
the age proﬁle of CRP suggested a simple linear decrease in inﬂamma-
tion with increasing age (Fig. 3A–D). The prevalence of asymptomatic
malaria parasitaemia increased with increasing age (Table 2). We
found no overall difference in hepcidin concentrations by sex in all
age groups combined (2·75 ng/ml; 2·11, 3·57 for females vs. 2·24;
1·80, 2·78 for males; p = 0·40 in an age-adjusted model), however
female infants had markedly higher concentrations (12·32 ng/ml; 95%
CI 7·54, 20·12) compared to male infants (5·79 ng/ml; 3·44, 9·76;
p = 0 · 009).
3.2. Hepcidin Concentration is Inﬂuenced by Iron Stores, Erythropoiesis and
Inﬂammation
Ferritin, sTfR, and CRP levels explained 37.5%, 37.3%, and 10.2% of the
variance in hepcidin concentrations respectively (p b 0.0005 for each).
Hepcidin concentrations were very low in children with ID
(0·71 ng/ml; 95% CI 0·55, 0·92) in comparison to those without
(6·64 ng/ml; 95% CI 5·71, 7·70; p b 0·0005). The best-ﬁt fractional
polynomials suggested that hepcidin concentrations increased with
increasing ferritin and CRP and decreased with increasing sTfR and
ferritin index (Fig. 2B–E). Inﬂammation (CRP ≥ 5 mg/l) was associated
with increased hepcidin concentrations (7·57 ng/ml; 95% CI 5·56,
10·31 compared to 1·91; 1·58, 2·30; p b 0·0005, in those without
inﬂammation).
3.3. Hepcidin Concentration is Positively Associated with Asymptomatic
Malaria
Hepcidin concentrations were more than doubled in individuals
with asymptomatic P. falciparum parasitaemia (5·29 ng/ml; 3·39,
8·25 compared to 2·18 ng/ml; 1·82, 2·61; p b 0·0005 in aparasitaemic
individuals) and malaria parasitaemia explained 7% of the variation in
hepcidin (p b 0·0005). Parasite density, ID, inﬂammation, and age
modiﬁed the effects of parasitaemia on hepcidin (Figs. 2F, 4). Among
parasitized children those with ID had markedly lower hepcidin con-
centrations compared to those without (1·41 ng/ml; 0·49, 4·0 vs.
8·14 ng/ml; 5·26, 12·6; p b 0·0005). Moreover, parasitaemia increased
hepcidin concentrations both in the absence and presence of inﬂamma-
tion (Fig. 4A). Hepcidin concentrations were higher among younger
parasitaemic children than older (13·47 ng/ml; for 3–5 years old
compared to 3·14 ng/ml for 5–8 years old; β -0·64; −0·27, −1·0;
p = 0 · 001, Figs. 2A and 4B). Similarly, ferritin levels were higher in
younger parasitaemic children (Fig. 3A), although CRP and parasite
density did not differ signiﬁcantly between age groups (Table 2).
3.4. Hepcidin Concentration is Positively Associated with Antibodies to
P. falciparum Antigens
We then assessed whether hepcidin concentrations correlated with
antibodies to P. falciparum antigens. In age-adjusted GEE-based models
hepcidin concentrations were positively associated with antibody titres
to schizont extract, AMA1, and MSP2 (β 0·41; 0·29, 0·53; p b 0·0005;
β 0·13; 0·02, 0·23; p = 0·02, and β 0·23; 0·13, 0·33; p b 0·0005 re-
spectively). We found a signiﬁcant interaction between age and anti-
body titres to AMA1 in predicting hepcidin concentrations (p = 0·01)
and a trend towards an interaction with MSP2 (p = 0·08), so that in
younger children a smaller unit change in AMA1 or MSP2 was associat-
ed with a much larger unit change in hepcidin compared with older
children. We found no interaction between age and antibody titres to
schizont extract in predicting hepcidin concentrations.
Table 1
Characteristics of study population (n = 324).
Characteristics
Median age, mthsa (range) 47·0 (4·9, 97·1)
Male sex, n (%) 177 (54·6)
Haemoglobin AS, n (%)b 45 (14·0)
α+thalassemia, n (%)c
αα/αα 95 (30·3)
αα/−α 162 (51·8)
−α/−α 56 (17·9)
Ethnic group, n (%)d
Giriama 279 (86·1)
Chonyi 28 (8·6)
Kauma 17 (5·3)
a Deﬁned as age at the mid-point of individual longitudinal follow up;
b 2 missing haemoglobin S type;
c 11 missing α+thalassaemia genotypes;
d Subgroups of the Mijikenda ethnic group.
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3.5. Recent Malaria, but not Non-malarial Fever, Alters Hepcidin
Concentrations
We next evaluated whether hepcidin concentrations varied with
time after a clinical malaria or non-malarial fever episode. The best-ﬁt
fractional polynomial of the time proﬁle of hepcidin after treatment
for clinical malaria suggested that hepcidin concentrations declined
steeply in the ﬁrst week, then more slowly over the subsequent weeks
(Fig. 5A). However, we found no signiﬁcant difference in hepcidin con-
centration attributable to non-malarial febrile illnesses (Fig. 5B).
3.6. Hepcidin Concentration does not Predict the Subsequent Risk ofMalaria
or Non-malarial Fever
Finally, we tested the hypothesis that hepcidin concentrations inﬂu-
ence the subsequent risk of malaria and non-malarial fever. Overall, we
observed 148 ﬁrst or only episodes of clinical malaria and 130 ﬁrst or
only episodes of non-malarial fever during 2402months of monitoring.
Survival plots for clinical malaria and non-malarial fever by hepcidin
tertile are shown in Fig. 6. In univariable Cox analyses we observed a
trend towards a reduced risk of clinical malaria with higher hepcidin
concentrations (HR 0.85; 0.71, 1.01; p = 0·07), an effect that was lost
on adjustment for other variables (adjusted HR 1.08; 0.90, 1.30; p =
0.41, Table 3). We similarly found no association between hepcidin
and the subsequent risk of non-malarial febrile illness (Table 3).
4. Discussion
Bothmalaria and ID are important public health problems in African
children. In the current study 12% of children were parasitaemic and
46% had ID. Hepcidin concentrations fell rapidly in infancy and then
more slowly with increasing age, while female infants had higher con-
centrations thanmales. We found that asymptomatic malaria was asso-
ciated with signiﬁcantly elevated hepcidin concentrations, which were
proportional to parasite density and modiﬁed by age, inﬂammation,
and the presence of ID. Furthermore, hepcidin was positively associated
with antibody titres to P. falciparum antigens. Concentrations fell rapidly
and then slowly after treatment of clinical malaria, but were not altered
by non-malarial febrile illnesses. Nevertheless, hepcidin concentrations
did not predict the subsequent risk of malaria or other febrile illnesses.
We found a non-linear association between age and hepcidin. In
agreement with a study in 3–12-month old Zimbabwean infants
(Mupfudze et al., 2014), hepcidin concentrations were the highest in
the youngest children and decreased dramatically in infancy (Fig. 2A).
We add to this that hepcidin concentrations are the highest in the ﬁrst
3 months of life. However, in contrast to European studies, which
showed either no change or an increase in hepcidin with age (Sdogou
et al., 2015; Cangemi et al., 2013), we found a slow decline in hepcidin
with increasing age. These ﬁndings might be explained by age-speciﬁc
differences in the strength of hepcidin stimuli (such as iron stores,
erythropoietic drive, and inﬂammation) (Fig. 3), and we hypothesize
that different environmental conditions may inﬂuence hepcidin
Fig. 2.Multiple fractional polynomials of determinants of hepcidin concentrationbymalaria parasitaemia. Scatter plot of log hepcidin concentration (y axis) against: A) age in years (x axis)
with the ﬁtted fractional polynomials: parasite positive (red): concentration =m1*(age in years) + c (n= 69); and parasite negative (black): concentration =m1*ln(age in years) + c
(n = 494); B) Log ferritin (x axis) with the ﬁtted fractional polynomials: parasite positive (red): concentration = m1*ln(ferritin) + c (n = 68); and parasite negative (black):
concentration = m1*ln(ln(ferritin + c1)) + m2*(ln(ln(ferritin + c1)))2 + c2 (n = 489); C) Log sTfR (x axis) with the ﬁtted fractional polynomials: parasite positive (red):
concentration = m1*ln(sTfR) + c (n = 69); and parasite negative (black): concentration = m1*(ln sTfR)3 + m2*(ln sTfR)3*ln(ln sTfR) + c1 (n = 488); D) Log ferritin index (x axis)
with the ﬁtted fractional polynomials: parasite positive (red): concentration = m1*ln(ferritin index) + c (n = 68); and parasite negative (black): concentration = m1*(ln(ferritin
index) + c1)3 + m2*(ln(ferritin index))3*ln(ln(ferritin index))3+ c2 (n = 475); E) Log CRP (x axis) with the ﬁtted fractional polynomials: parasite positive (red): concentration =
m1*(ln(CRP) + c1)2 + c2 (n= 68); and parasite negative (black): concentration =m1*ln(CRP) + c (n= 489); F) P. falciparum parasite density, parasites/μl (x axis) with the ﬁtted frac-
tional polynomial: Concentration = m1*ln(parasite density) + c (n = 69). Dotted lines indicate 95% conﬁdence intervals.
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signalling at varying ages in European children. In agreement with a
study in Kenyan infants (Jaeggi et al., 2013), we found that hepcidin
concentrations were about twice as high in female infants compared
to males.
Ferritin, sTfR and CRP explained 37·5%, 37·3%, and 10·2% of the var-
iance in hepcidin respectively (p b 0·0005 for each). In agreement with
a study in Indonesian school children (deMast et al., 2010), asymptom-
atic malaria was also associated with an increase in plasma hepcidin
Fig. 3.Multiple fractional polynomials of the age proﬁle of iron status and inﬂammation bymalaria parasitaemia. Scatterplots of age in years (x axis) against A) log ferritin with the ﬁtted frac-
tional polynomials: for parasite positive (red): concentration=m1*(age in years)+c(n=69); andparasitenegative (black): concentration=m1*ln(age inyears)+m2*(ln(age inyears))2+-
c (n = 496); B) log soluble transferrin receptor with the ﬁtted fractional polynomials: for parasite positive (red): concentration = m1*(age in years) + c (n = 70); and parasite negative
(black): concentration = m1*(age in years)−0.5 + m2*(age in years)−0.5 *ln(age in years) + c (n = 498); C) log ferritin index with the ﬁtted fractional polynomials for parasite positive
(red): concentration =m1*(age in years) + c (n = 69); and parasite negative (black): concentration =m1*(age in years)−0.5 + m2*ln(age in years) + c (n = 481); and D) log CRP with
the ﬁtted fractional polynomials: for parasite positive (red): concentration =m1*(age in years) + c (n = 69); and parasite negative (black): concentration =m1*(age in years) + c (n =
496). Dotted lines indicate 95% conﬁdence intervals.
Table 2
Effects of age on hepcidin, inﬂammation and iron status by malaria parasitaemia.
Age, years
0–1 year 1–3 years 3–5 years 5–8 years
Number, (%) 63 (10·6) 161 (27·1) 142 (24·0) 227 (38·3)
Malaria parasitaemia, n (%) 1 /62 (1·6) 10/155 (6·5) 21/141 (14·9) 38/224 (17·0)
Parasite density, parasites/μL 120 1660 (327, 8406) 984 (380, 2545) 783 (407, 1505)
Hepcidin, ng/ml All 8·39 (5·85, 12·05) 2·49 (1·82, 3·41) 3·30 (2·39, 4·55) 1·47 (1·11, 1·95)
Parasite + ve 7·05 4·92 (1·15, 21·15) 13·47 (7·35, 24·70) 3·14 (1·66, 5·95)
Parasite -ve 8·42 (5·83, 12·17) 2·31 (1·66, 3·21) 2·56 (1·81, 3·64) 1·25 (0·91, 1·70)
CRP, mg/L All 2·08 (1·44, 3·02) 1·29 (1·07, 1·57) 1·55 (1·22, 1·96) 0·89 (0·79, 1·02)
Parasite + ve 29 2·48 (0·75, 8·14) 3·28 (1·45, 7·44) 1·74 (1·08, 2·78)
Parasite -ve 1·99 (1·38, 2·87) 1·20 (1·0, 1·46) 1·32 (1·05, 1·67) 0·79 (0·70, 0·89)
Ferritin, μg/L All 27·7 (19·5, 39·4) 11·0 (9·4, 13·0) 18·1 (15·3, 21·4) 14·8 (13·0, 16·9)
Parasite + ve 106 30·4 (12·8, 72·3) 42·6 (29·3, 62·0) 21·5 (15·0, 30·8)
Parasite -ve 27·0 (19·0, 38·6) 10·2 (8·7, 12·0) 15·4 (12·9, 18·3) 13·9 (12·1, 15·9)
sTfR, mg/L All 3·44 (3·09, 3.83) 3·92 (3·72, 4·13) 3·38 (3·19, 3·58) 3·74 (3·53, 3·96)
Parasite + ve 5·09 4·49 (3·61, 5·58) 3·02 (2·74, 3·32) 3·71 (3·19, 4·32)
Parasite -ve 3·42 (3·07, 3·81) 3·88 (3·67, 4·11) 3·46 (3·24, 3·69) 3·74 (3·51, 3·98)
Ferritin index All 2·54 (2·08, 3·09) 3·85 (3·48, 4·25) 2·82 (2·55, 3·11) 3·29 (3·00, 3·61)
Parasite + ve 2·51 3·19 (2·05, 4·97) 1·89 (1·63, 2·19) 3·04 (2·33, 3·97)
Parasite -ve 2·54 (2·08, 3·10) 3·90 (3·51, 4·34) 3·05 (2·73, 3·40) 3·35 (3·04, 3·69)
Abbreviations: CRP, C-reactive protein; sTfR, soluble transferrin receptors. Parasite + ve indicates the presence of malaria parasites on routine blood smear. Unless otherwise indicated
numbers are geometric means with 95% conﬁdence intervals in brackets.
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(explaining 7% of variance; p b 0·0005), both in the presence and ab-
sence of inﬂammation, suggesting that malaria regulates hepcidin via
non-inﬂammatory, as well as inﬂammatory pathways (Armitage et al.,
2009). We add that hepcidin levels are proportional to parasite density
in asymptomatic infection, as observed in febrilemalaria (Howard et al.,
2007; Casals-Pascual et al., 2012), but not in severe infection (Burte
et al., 2013). Hepcidin concentrations were markedly higher in younger
compared to older parasitized children, suggesting that iron absorption
is more likely to be impaired in younger children. Finally, among chil-
dren with parasitaemia, hepcidin levels were markedly lower in those
with ID than those without ID, suggesting that malaria-mediated up-
regulating stimuli may be overruled by iron demand and erythropoietic
Fig. 4.Malaria parasitaemia and inﬂammation inﬂuence hepcidin concentrations. Geometric mean hepcidin concentrations (and 95% conﬁdence intervals) by malaria parasitaemia and
inﬂammation for: A) all children and B) according to age group. P values are derived from GEE-based regression models, and analyses that included all ages were adjusted for age.
Fig. 5.Hepcidin concentrations following clinical malaria and non-malarial febrile illness. Scatterplots of log hepcidin concentration (y axis) against time since A) last clinical malarial ep-
isode (x axis) with ﬁtted fractional polynomial, concentrations=m1*(time since last clinical malarial episode) + c and B) last febrile non-malarial episode with ﬁtted fractional polyno-
mial, concentrations = m1*(time since last febrile non-malarial episode) + c. Time was restricted to a 3 month period prior to hepcidin measurement.
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stimuli down-regulating hepcidin synthesis. Thus, children with ID and
parasitaemia might be in danger of receiving iron if hepcidin-guided
supplementation was implemented without malaria screening.
Antibodies to malaria antigens are sensitive biomarkers of
population-level malaria exposure and may be useful surveillance tools
for malaria control and elimination (Elliott et al., 2014). We investigated
whether malaria antibodies might reﬂect malaria-induced hepcidin
levels. We found that plasma hepcidin concentrations were strongly pos-
itively associated with antibodies to P. falciparum antigens in age-
adjusted models. For AMA1 and MSP2 we found interactions between
age and antibody titres so that in younger children a small increase in an-
tibody titres was associated with a large increase in hepcidin concentra-
tions, while in older children increased antibody titres had little effect
on hepcidin. This agrees with our study showing that these antibodies
act as measures of exposure in younger children with lower immunity
and asmeasures of protective immunity in older childrenwith higher an-
tibody titres (Stanisic et al., 2015). By contrast antibodies to schizont ex-
tract were strongly positively associated with hepcidin concentrations
regardless of age, which might be explained by their shorter half-life
and high rates of sero-reversion at all ages (Ondigo et al., 2014). Taken to-
gether, these data suggest that sero-surveillance tools may be of use to
identify population-level malaria-induced hepcidin, particularly in youn-
ger children,with relevance to programmes to restore healthy iron status.
We next evaluated the proﬁle of hepcidin concentrations over a
3-month period after exposure to and treatment of febrile clinical
malaria. In agreement with other studies in African children we found
that concentrations were initially very high (Howard et al., 2007; de
Mast et al., 2009; Casals-Pascual et al., 2012; Burte et al., 2013); but fell
very rapidly in the ﬁrst week following treatment of febrile malaria and
more slowly in the subsequent weeks (Fig. 5A) (de Mast et al., 2009;
Casals-Pascual et al., 2012). Contrary to expectations, non-malarial febrile
illnesses were not signiﬁcantly associated with hepcidin concentrations
(Fig. 5B), although the fact that diagnoses were not assigned to non-
malarial febrile illnesses is a limitation of the study. However, in agree-
ment with this ﬁnding, children with both inﬂammation and malaria
hadmarkedly higher hepcidin concentrations than thosewith inﬂamma-
tion alone (p b 0.0005, Fig. 4A), suggesting that malaria may have amore
pronounced effect on hepcidin synthesis than other febrile illnesses.
Finally we hypothesized that hepcidin concentrations might inﬂu-
ence the subsequent risk of malaria. Intriguing data frommouse studies
suggest that hepcidin might play a role in modulating clinical malaria
(Wang et al., 2011; Portugal et al., 2011), but we are not aware of any
previous studies that have investigated this possibility in humans.
After adjustment for potential confounders, we found no signiﬁcant
association between hepcidin and the subsequent risk of either
P. falciparummalaria or non-malarial fever. A number of possible expla-
nations can be put forward for this negative ﬁnding. It is possible that, in
contrast to mouse studies (Wang et al., 2011), hepcidin concentrations
are not associated with severity of malaria or other infections in
humans, perhaps due to hepcidin-independent iron restriction (Guida
et al., 2015). However, if they are, wemay have failed to detect an effect
for a number of reasons. Firstly, baseline hepcidin may not inﬂuence
hepcidin at the timeof, or just prior to, acutemalaria infection and a lim-
itation of our study is that hepcidin was not measured routinely at the
time of acute malaria. Second, given that hepcidin is controlled by
multiple competing stimuli (Huang et al., 2009), hepcidinmight only in-
ﬂuence the subsequent risk of infection when very strong down-
regulatory signals from ID and erythropoietic drive overwhelm weaker
up-regulatory signals frommalaria and other infections (Casals-Pascual
et al., 2012; Jonker et al., 2013). However, the study cohort consisted of
‘healthy’ community-based children. Finally, theremay also be counter-
Fig. 6.Kaplan–Meier curves of A) time to ﬁrst clinicalmalarial episode according to tertile of hepcidin concentration (p=0.43 for 1st tertile vs. 2nd tertile and p=0.07 for 1st tertile vs. 3rd
tertile); and B) time to ﬁrst non-malarial fever episode according to tertile of hepcidin concentration (p= 0.50 for 1st tertile vs. 2nd tertile and p= 0.18 for 1st tertile vs. 3rd tertile). The
range of hepcidin concentration for each hepcidin tertile was: 0·04–1·60 ng/ml for the 1st tertile; 1·61–7·49 ng/ml for the 2nd tertile; and 7·50–122·47 ng/ml for the 3rd tertile. P values
are derived from Cox regression models.
Table 3
Cox regression models for risk of clinical malaria and non-malarial fever by hepcidin
concentrations.
Clinical malariaa HR (95% CI) p Adjusted
HR (95% CI)
p
Log Hepcidin (ng/ml) 0·85 (0·71, 1·01) 0·07 1·08 (0·90, 1·30) 0·41
Hepcidin tertiles
Hepcidin tertile 1 Reference – Reference –
Hepcidin tertile 2 0·85 (0·58, 1·26) 0·43 1·07 (0·72, 1·58) 0·75
Hepcidin tertile 3 0·68 (0·45, 1·04) 0·07 1·00 (0·63, 1·58) 1·00
Non-malarial feverb HR (95% CI) p Adjusted
HR (95% CI)
p
Log hepcidin (ng/ml) 1·13 (0·91, 1·40) 0·25 1·02 (0·81, 1·27) 0·88
Hepcidin tertiles
Hepcidin tertile 1 Reference – Reference –
Hepcidin tertile 2 1·16 (0·75, 1·79) 0·50 1·05 (0·67, 1·63) 0·84
Hepcidin tertile 3 1·34 (0·87, 2·05) 0·18 1·12 (0·72, 1·74) 0·61
Abbreviations: HR, hazard ratio; CI, conﬁdence interval. HRs and 95% CIs are shown for
each log fold increase in hepcidin level and by hepcidin tertiles (tertile 1 = 0·04–1·60
ng/ml; tertile 2 = 1·61–7·49 ng/ml; tertile 3 = 7·50–122·47 ng/ml).
a Deﬁned as a fever (axillary temperature ≥37·5 °C) in conjunction with a positive
blood ﬁlm at any density for children age b1 year or at a density of N2500 parasites/μl for
children aged ≥1 year (Mwangi et al., 2005). For clinicalmalaria HRswere adjusted for age
in years, ethnicity, sickle cell trait, and period of monitoring.
b Deﬁned as a fever in conjunction with a negative blood ﬁlm. For non-malarial fever
HRs were adjusted for age in years and period of monitoring.
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balancing effects, for example a reduced risk of malaria due to ID
(Nyakeriga et al., 2004; Gwamaka et al., 2012)may counter a protective
effect of higher hepcidin concentrations: all questions for future studies.
In conclusion, we have shown that asymptomatic and recent febrile
malaria both signiﬁcantly increase hepcidin in a population of children
where ID is an important cause of morbidity. Given that dietary iron ab-
sorption is impaired by elevated hepcidin (Cercamondi et al.; 2010;
Prentice et al., 2012;Glinz et al., 2015), our data suggest that asymptom-
atic and febrilemalaria contribute to the high prevalence of ID in African
children. Unless malaria episodes are controlled, iron supplementation
may be ineffective because of hepcidin-mediated poor iron absorption.
Strategies to prevent and eliminate malaria may therefore have the
added beneﬁt of addressing an important cause of ID for children living
in sub-Saharan Africa.
Abbreviations
ID iron deﬁciency
GEE generalized estimating equation
AMA1 apical membrane antigen 1
MSP2 merozoite surface protein 2
CRP C-reactive protein
HR hazard ratio
Author contributions
SHA, HD, AMP, JGB, TNW, SK, SMU, CKM, AEA, and PB wrote the
manuscript. SHA, HD, AEA, and TNW conceived the study. All authors
contributed to the design of the study. SK, SMU, and CKM performed
laboratory analyses and data collection, SK performed hepcidin and
iron measurements and SHA and PB performed all statistical analyses.
Declaration of interests
All authors declare no conﬂicts of interest.
Acknowledgements
We thank the study participants, their families, the ﬁeld staff and
study co-ordinators and the staff of the human genetics laboratory at
the KEMRI-Wellcome Trust Programme including Alex Macharia,
Emily Nyatichi, Metrine Tendwa, Johnstone Makale, Gideon Nyutu,
and Ruth Mwarabu for their help with sample processing and database
support, and Robin Anders for providing recombinant AMA1 andMSP2
antigens.
This paper is published with the permission of the Director of the
Kenya Medical Research Institute.
References
Arezes, J., Jung, G., Gabayan, V., Valore, E., Ruchala, P., Gulig, P.A., Ganz, T., Nemeth, E.,
Bulut, Y., 2015. Hepcidin-induced hypoferremia is a critical host defense mechanism
against the siderophilic bacterium Vibrio vulniﬁcus. Cell Host Microbe 17 (1), 47–57.
Armitage, P., Berry, G., Matthews, J., 2001. Using STATA's robust cluster command as ap-
propriate. Statistical Methods in Medical Research 4th ed. Oxford Blackwell Scientiﬁc
Publications.
Armitage, A.E., Pinches, R., Eddowes, L.A., Newbold, C.I., Drakesmith, H., 2009. Plasmodium
falciparum infected erythrocytes induce hepcidin (HAMP) mRNA synthesis by
peripheral blood mononuclear cells. Br. J. Haematol. 147 (5), 769–771.
Atkinson, S.H., Armitage, A.E., Khandwala, S., Mwangi, T.W., Uyoga, S., Bejon, P.A.,
Williams, T.N., Prentice, A.M., Drakesmith, H., 2014. Combinatorial effects of malaria
season, iron deﬁciency, and inﬂammation determine plasma hepcidin concentration
in African children. Blood 123 (21), 3221–3229.
Ayoya, M.A., Stoltzfus, R.J., Spiekermann-Brouwer, G.M., Nemeth, E., Traore, A.K., Ganz, T.,
Garza, C., 2009. Hepcidin and Plasmodium falciparum malaria in anemic school chil-
dren in Mali. Bull. Soc. Pathol. Exot. 102 (4), 219–220.
Black, M.M., Quigg, A.M., Hurley, K.M., Pepper, M.R., 2011. Iron deﬁciency and iron-
deﬁciency anemia in the ﬁrst two years of life: strategies to prevent loss of develop-
mental potential. Nutr. Rev. 69 (Suppl. 1), S64–S70.
Burte, F., Brown, B.J., Orimadegun, A.E., Ajetunmobi, W.A., Afolabi, N.K., Akinkunmi, F.,
Kowobari, O., Omokhodion, S., Osinusi, K., Akinbami, F.O., Shokunbi, W.A., Sodeinde,
O., Fernandez-Reyes, D., 2013. Circulatory hepcidin is associated with the anti-
inﬂammatory response but not with iron or anemic status in childhood malaria.
Blood 121 (15), 3016–3022.
Cangemi, G., Pistorio, A., Miano, M., Gattorno, M., Acquila, M., Bicocchi, M.P., Gastaldi, R.,
Riccardi, F., Gatti, C., Fioredda, F., Calvillo, M., Melioli, G., Martini, A., Dufour, C.,
2013. Diagnostic potential of hepcidin testing in pediatrics. Eur. J. Haematol. 90 (4),
323–330.
Casals-Pascual, C., Huang, H., Lakhal-Littleton, S., Thezenas, M.L., Kai, O., Newton, C.R.,
Roberts, D.J., 2012. Hepcidin demonstrates a biphasic association with anemia in
acute Plasmodium falciparum malaria. Haematologica 97 (11), 1695–1698.
Cercamondi, C.I., Egli, I.M., Ahouandjinou, E., Dossa, R., Zeder, C., Salami, L., Tjalsma, H.,
Wiegerinck, E., Tanno, T., Hurrell, R.F., Hounhouigan, J., Zimmermann, M.B., 2010. Afe-
brile Plasmodium falciparum parasitemia decreases absorption of fortiﬁcation iron
but does not affect systemic iron utilization: a double stable-isotope study in young
Beninese women. Am. J. Clin. Nutr. 92 (6), 1385–1392.
Chong, S.S., Boehm, C.D., Higgs, D.R., Cutting, G.R., 2000. Single-tube multiplex-PCR
screen for common deletional determinants of alpha-thalassemia. Blood 95 (1),
360–362.
de Mast, Q., Nadjm, B., Reyburn, H., Kemna, E.H., Amos, B., Laarakkers, C.M., Silalye, S.,
Verhoef, H., Sauerwein, R.W., Swinkels, D.W., van der Ven, A.J., 2009. Assessment of
urinary concentrations of hepcidin provides novel insight into disturbances in iron
homeostasis during malarial infection. J. Infect. Dis. 199 (2), 253–262.
de Mast, Q., Syafruddin, D., Keijmel, S., Riekerink, T.O., Deky, O., Asih, P.B., Swinkels, D.W.,
van der Ven, A.J., 2010. Increased serum hepcidin and alterations in blood
iron parameters associated with asymptomatic P. falciparum and P. vivax malaria.
Haematologica 95 (7), 1068–1074.
Drakesmith, H., Prentice, A.M., 2012. Hepcidin and the iron-infection axis. Science 338
(6108), 768–772.
Elliott, S.R., Fowkes, F.J., Richards, J.S., Reiling, L., Drew, D.R., Beeson, J.G., 2014. Research
priorities for the development and implementation of serological tools for malaria
surveillance. F1000prime reports 6 p. 100.
Ganz, T., 2009. Iron in innate immunity: starve the invaders. Curr. Opin. Immunol. 21 (1),
63–67.
Ganz, T., 2011. Hepcidin and iron regulation, 10 years later. Blood 117 (17),
4425–4433.
Ganz, T., 2013. Systemic iron homeostasis. Physiol. Rev. 93 (4), 1721–1741.
Glinz, D., Hurrell, R.F., Righetti, A.A., Zeder, C., Adiossan, L.G., Tjalsma, H., Utzinger, J.,
Zimmermann, M.B., N'Goran, E.K., Wegmuller, R., 2015. In Ivorian school-age
children, infection with hookworm does not reduce dietary iron absorption or
systemic iron utilization, whereas afebrile Plasmodium falciparum infection reduces
iron absorption by half. Am. J. Clin. Nutr. 101 (3), 462–470.
Guida, C., Altamura, S., Klein, F.A., Galy, B., Boutros, M., Ulmer, A.J., Hentze, M.W.,
Muckenthaler, M.U., 2015. A novel inﬂammatory pathway mediating rapid
hepcidin-independent hypoferremia. Blood 125 (14), 2265–2275.
Gwamaka, M., Kurtis, J.D., Sorensen, B.E., Holte, S., Morrison, R., Mutabingwa, T.K., Fried,
M., Duffy, P.E., 2012. Iron deﬁciency protects against severe Plasmodium falciparum
malaria and death in young children. Clin. Infect. Dis. 54 (8), 1137–1144.
Houngbedji, C.A., N'Dri, P.B., Hurlimann, E., Yapi, R.B., Silue, K.D., Soro, G., Koudou, B.G.,
Acka, C.A., Assi, S.B., Vounatsou, P., N'Goran, E.K., Fantodji, A., Utzinger, J., Raso, G.,
2015. Disparities of Plasmodium falciparum infection, malaria-related morbidity and
access to malaria prevention and treatment among school-aged children: a national
cross-sectional survey in Cote d'Ivoire. Malar. J. 14 (1), 7.
Howard, C.T., McKakpo, U.S., Quakyi, I.A., Bosompem, K.M., Addison, E.A., Sun, K., Sullivan,
D., Semba, R.D., 2007. Relationship of hepcidin with parasitemia and anemia among
patients with uncomplicated Plasmodium falciparum malaria in Ghana. Am. J. Trop.
Med. Hyg. 77 (4), 623–626.
Huang, H., Constante, M., Layoun, A., Santos, M.M., 2009. Contribution of STAT3 and
SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood 113
(15), 3593–3599.
Jaeggi, T., Moretti, D., Kvalsvig, J., Holding, P.A., Tjalsma, H., Kortman, G.A., Joosten, I.,
Mwangi, A., Zimmermann, M.B., 2013. Iron status and systemic inﬂammation, but
not gut inﬂammation, strongly predict gender-speciﬁc concentrations of serum
hepcidin in infants in rural Kenya. PLoS One 8 (2), e57513.
Jonker, F.A., Calis, J.C., Phiri, K., Kraaijenhagen, R.J., Brabin, B.J., Faragher, B., Wiegerinck,
E.T., Tjalsma, H., Swinkels, D.W., van Hensbroek, M.B., 2013. Low hepcidin levels in se-
verely anemicMalawian children with high incidence of infectious diseases and bone
marrow iron deﬁciency. PLoS One 8 (12), e78964.
Mugyenyi, C.K., Elliott, S.R., McCallum, F.J., Anders, R.F., Marsh, K., Beeson, J.G., 2013.
Antibodies to polymorphic invasion-inhibitory and non-inhibitory epitopes of
Plasmodium falciparum apical membrane antigen 1 in human malaria. PLoS One 8
(7), e68304.
Mupfudze, T.G., Stoltzfus, R.J., Rukobo, S., Moulton, L.H., Humphrey, J.H., Prendergast, A.J.,
Team, S.P., 2014. Hepcidin decreases over the ﬁrst year of life in healthy African in-
fants. Br. J. Haematol. 164 (1), 150–153.
Mwangi, T.W., Ross, A., Snow, R.W., Marsh, K., 2005. Case deﬁnitions of clinical malaria
under different transmission conditions in Kiliﬁ District, Kenya. J. Infect. Dis. 191
(11), 1932–1939.
Nyakeriga, A.M., Troye-Blomberg, M., Dorfman, J.R., Alexander, N.D., Back, R., Kortok, M.,
Chemtai, A.K., Marsh, K., Williams, T.N., 2004. Iron deﬁciency and malaria among
children living on the coast of Kenya. J. Infect. Dis. 190 (3), 439–447.
Ondigo, B.N., Hodges, J.S., Ireland, K.F., Magak, N.G., Lanar, D.E., Dutta, S., Narum, D.L., Park,
G.S., Ofulla, A.V., John, C.C., 2014. Estimation of recent and long-term malaria
transmission in a population by antibody testing to multiple Plasmodium falciparum
antigens. J. Infect. Dis. 210 (7), 1123–1132.
Portugal, S., Carret, C., Recker, M., Armitage, A.E., Goncalves, L.A., Epiphanio, S., Sullivan, D.,
Roy, C., Newbold, C.I., Drakesmith, H., Mota, M.M., 2011. Host-mediated regulation of
superinfection in malaria. Nat. Med. 17 (6), 732–737.
1485S.H. Atkinson et al. / EBioMedicine 2 (2015) 1478–1486
Prentice, A.M., Doherty, C.P., Abrams, S.A., Cox, S.E., Atkinson, S.H., Verhoef, H., Armitage,
A.E., Drakesmith, H., 2012. Hepcidin is the major predictor of erythrocyte iron incor-
poration in anemic African children. Blood 119 (8), 1922–1928.
Punnonen, K., Irjala, K., Rajamaki, A., 1997. Serum transferrin receptor and its ratio to
serum ferritin in the diagnosis of iron deﬁciency. Blood 89 (3), 1052–1057.
Royston, P., Altman, D.G., 1994. Regression using fractional polynomials of continuous
covariates: parsimonious parametric modelling. Appl. Stat. 43, 429–467.
Sdogou, T., Tsentidis, C., Gourgiotis, D., Marmarinos, A., Gkourogianni, A., Papassotiriou, I.,
Anastasiou, T., Kossiva, L., 2015. Immunoassay-based serum hepcidin reference range
measurements in healthy children: differences among age groups. J. Clin. Lab. Anal.
29 (1), 10–14.
Stanisic, D.I., Fowkes, F.J., Koinari, M., Javati, S., Lin, E., Kiniboro, B., Richards, J.S., Robinson,
L.J., Schoﬁeld, L., Kazura, J.W., King, C.L., Zimmerman, P., Felger, I., Siba, P.M., Mueller,
I., Beeson, J.G., 2015. Acquisition of antibodies against Plasmodium falciparummerozo-
ites and malaria immunity in young children and the inﬂuence of age, force of infec-
tion, and magnitude of response. Infect. Immun. 83 (2), 646–660.
Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K.,
Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn,
S.Y., Ali, M.K., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson,
C., Baddour, L.M., Bahalim, A.N., Barker-Collo, S., Barrero, L.H., Bartels, D.H., Basanez,
M.G., Baxter, A., Bell, M.L., Benjamin, E.J., Bennett, D., Bernabe, E., Bhalla, K., Bhandari,
B., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Black, J.A., Blencowe, H., Blore, J.D., Blyth,
F., Bolliger, I., Bonaventure, A., Boufous, S., Bourne, R., Boussinesq, M., Braithwaite, T.,
Brayne, C., Bridgett, L., Brooker, S., Brooks, P., Brugha, T.S., Bryan-Hancock, C., Bucello,
C., Buchbinder, R., Buckle, G., Budke, C.M., Burch, M., Burney, P., Burstein, R., Calabria,
B., Campbell, B., Canter, C.E., Carabin, H., Carapetis, J., Carmona, L., Cella, C., Charlson,
F., Chen, H., Cheng, A.T., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S.,
Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de
Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahiya,
M., Dahodwala, N., Damsere-Derry, J., Danaei, G., Davis, A., De Leo, D., Degenhardt, L.,
Dellavalle, R., Delossantos, A., Denenberg, J., Derrett, S., Des Jarlais, D.C., Dharmaratne,
S.D., Dherani, M., Diaz-Torne, C., Dolk, H., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B.,
Edmond, K., Elbaz, A., Ali, S.E., Erskine, H., Erwin, P.J., Espindola, P., Ewoigbokhan,
S.E., Farzadfar, F., Feigin, V., Felson, D.T., Ferrari, A., Ferri, C.P., Fevre, E.M., Finucane,
M.M., Flaxman, S., Flood, L., Foreman, K., Forouzanfar, M.H., Fowkes, F.G., Franklin,
R., Fransen, M., Freeman, M.K., Gabbe, B.J., Gabriel, S.E., Gakidou, E., Ganatra, H.A.,
Garcia, B., Gaspari, F., Gillum, R.F., Gmel, G., Gosselin, R., Grainger, R., Groeger, J.,
Guillemin, F., Gunnell, D., Gupta, R., Haagsma, J., Hagan, H., Halasa, Y.A., Hall, W., Har-
ing, D., Haro, J.M., Harrison, J.E., Havmoeller, R., Hay, R.J., Higashi, H., Hill, C., Hoen, B.,
Hoffman, H., Hotez, P.J., Hoy, D., Huang, J.J., Ibeanusi, S.E., Jacobsen, K.H., James, S.L.,
Jarvis, D., Jasrasaria, R., Jayaraman, S., Johns, N., Jonas, J.B., Karthikeyan, G., Kassebaum,
N., Kawakami, N., Keren, A., Khoo, J.P., King, C.H., Knowlton, L.M., Kobusingye, O.,
Koranteng, A., Krishnamurthi, R., Lalloo, R., Laslett, L.L., Lathlean, T., Leasher, J.L., Lee,
Y.Y., Leigh, J., Lim, S.S., Limb, E., Lin, J.K., Lipnick, M., Lipshultz, S.E., Liu, W., Loane,
M., Ohno, S.L., Lyons, R., Ma, J., Mabweijano, J., MacIntyre, M.F., Malekzadeh, R.,
Mallinger, L., Manivannan, S., Marcenes, W., March, L., Margolis, D.J., Marks, G.B.,
Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott,
M.M., McGill, N., McGrath, J., Medina-Mora, M.E., Meltzer, M., Mensah, G.A.,
Merriman, T.R., Meyer, A.C., Miglioli, V., Miller, M., Miller, T.R., Mitchell, P.B.,
Mocumbi, A.O., Mofﬁtt, T.E., Mokdad, A.A., Monasta, L., Montico, M., Moradi-Lakeh,
M., Moran, A., Morawska, L., Mori, R., Murdoch, M.E., Mwaniki, M.K., Naidoo, K.,
Nair, M.N., Naldi, L., Narayan, K.M., Nelson, P.K., Nelson, R.G., Nevitt, M.C., Newton,
C.R., Nolte, S., Norman, P., Norman, R., O'Donnell, M., O'Hanlon, S., Olives, C., Omer,
S.B., Ortblad, K., Osborne, R., Ozgediz, D., Page, A., Pahari, B., Pandian, J.D., Rivero,
A.P., Patten, S.B., Pearce, N., Padilla, R.P., Perez-Ruiz, F., Perico, N., Pesudovs, K., Phillips,
D., Phillips, M.R., Pierce, K., Pion, S., Polanczyk, G.V., Polinder, S., Pope III, C.A., Popova,
S., Porrini, E., Pourmalek, F., Prince, M., Pullan, R.L., Ramaiah, K.D., Ranganathan, D.,
Razavi, H., Regan, M., Rehm, J.T., Rein, D.B., Remuzzi, G., Richardson, K., Rivara, F.P.,
Roberts, T., Robinson, C., De Leon, F.R., Ronfani, L., Room, R., Rosenfeld, L.C., Rushton,
L., Sacco, R.L., Saha, S., Sampson, U., Sanchez-Riera, L., Sanman, E., Schwebel, D.C.,
Scott, J.G., Segui-Gomez, M., Shahraz, S., Shepard, D.S., Shin, H., Shivakoti, R., Singh,
D., Singh, G.M., Singh, J.A., Singleton, J., Sleet, D.A., Sliwa, K., Smith, E., Smith, J.L.,
Stapelberg, N.J., Steer, A., Steiner, T., Stolk, W.A., Stovner, L.J., Sudfeld, C., Syed, S.,
Tamburlini, G., Tavakkoli, M., Taylor, H.R., Taylor, J.A., Taylor, W.J., Thomas, B., Thom-
son, W.M., Thurston, G.D., Tleyjeh, I.M., Tonelli, M., Towbin, J.A., Truelsen, T.,
Tsilimbaris, M.K., Ubeda, C., Undurraga, E.A., van der Werf, M.J., van Os, J., Vavilala,
M.S., Venketasubramanian, N., Wang, M., Wang, W., Watt, K., Weatherall, D.J.,
Weinstock, M.A., Weintraub, R., Weisskopf, M.G., Weissman, M.M., White, R.A.,
Whiteford, H., Wiersma, S.T., Wilkinson, J.D., Williams, H.C., Williams, S.R., Witt, E.,
Wolfe, F., Woolf, A.D., Wulf, S., Yeh, P.H., Zaidi, A.K., Zheng, Z.J., Zonies, D., Lopez,
A.D., Murray, C.J., AlMazroa, M.A., Memish, Z.A., 2012. Years lived with disability
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic anal-
ysis for the Global Burden of Disease Study 2010. Lancet 380 (9859), 2163–2196.
Wang, H.Z., He, Y.X., Yang, C.J., Zhou, W., Zou, C.G., 2011. Hepcidin is regulated during
blood-stage malaria and plays a protective role in malaria infection. J. Immunol.
187 (12), 6410–6416.
WHO, 2014. World Malaria Report. World Health Organization, Geneva, Switzerland.
WHO, CDC, 2007. Assessing the iron status of populations: report of a joint World Health
Organization/Centers for Disease Control and Prevention technical consultation on
the assessment of iron status at the population level. World Health Organization,
Geneva, Switzerland.
WHO/UNICEF/UNU, 2001. Iron deﬁciency anaemia: assessment, prevention, and control.
A guide for Programme Managers. World Health Organization, Geneva, Switzerland.
1486 S.H. Atkinson et al. / EBioMedicine 2 (2015) 1478–1486
